Business description: Incyte Corporation

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:

- product sales (84.7%);

- royalties (12.4%);

- income from research and cooperation agreements (2.9%).

Number of employees: 2,844

Sales by Activity: Incyte Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Oncology and Dermatology Pharmaceutical Products

298.63Cr 339.46Cr 369.56Cr 424.12Cr 514.12Cr

Geographical breakdown of sales: Incyte Corporation

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

290Cr 320Cr 350Cr 400Cr 479.99Cr

Europe

12Cr 15Cr - 26Cr 32Cr

Other Countries

- - - 62L 1.76Cr

Europe and Japan

- - 18Cr - -

Executive Committee: Incyte Corporation

Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Chief Tech/Sci/R&D Officer 62 01/01/2016
Chief Tech/Sci/R&D Officer 59 02/03/2015

Composition of the Board of Directors: Incyte Corporation

Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Director/Board Member 64 14/11/2017
Director/Board Member 73 16/12/2019
Director/Board Member 74 25/03/2020
Director/Board Member 66 27/09/2021
Director/Board Member 58 26/06/2025

Shareholders: Incyte Corporation

NameEquities%Valuation
Baker Bros. Advisors LP
15.58 %
3,10,06,757 15.58 % 2 954 M $
Baker Bros. Advisors LP
15.45 %
3,07,43,991 15.45 % 2 929 M $
BlackRock Advisors LLC
7.039 %
1,40,07,975 7.039 % 1 335 M $
Dodge & Cox
6.664 %
1,32,61,742 6.664 % 1 263 M $
Vanguard Capital Management LLC
6.327 %
1,25,91,630 6.327 % 1 200 M $

Holdings: Incyte Corporation

NameEquities%Valuation
43,72,124 9.06% 23 M $

Company details: Incyte Corporation

Incyte Corp.

1801 Augustine Cut-Off

19803, Wilmington

+302 498 6700

http://www.incyte.com
address Incyte Corporation(INCY)

Biopharmaceuticals

Change 5d. change 1-year change 3-years change Capi.($)
+1.79%+3.27%+64.86%+56.33% 1.97TCr
-0.30%+0.50%+23.82%-4.40% 7.27TCr
+0.73%+1.99%+52.77%+179.58% 5.25TCr
-0.95%+45.80%+45.80%+45.80% 4.66TCr
-15.96%-19.30%-57.90%-66.77% 4.21TCr
+2.33%+5.74%+59.12%-36.26% 2.86TCr
-2.70%+11.80%+105.76%-58.82% 2.16TCr
-1.94%-1.94%+68.42%+122.57% 1.99TCr
+2.02%+3.79%+48.10%+99.28% 1.63TCr
-4.02%-6.25%+81.28%+353.58% 1.32TCr
Average -1.81%+2.23%+49.20%+69.09% 3.33TCr
Weighted average by Cap. -2.09%+1.55%+38.01%+47.89%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
98.56USD
Average target price
108.50USD
Spread / Average Target
+10.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. INCY Stock
  4. Company Incyte Corporation